Arpida Presents Preclinical and Clinical Data on Iclapri... (structure infections. An NDA filing is e...)

Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC

Date:9/19/2007

structure infections. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpidas fourth most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of first-in-man studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, e
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. BioRobot MDx standardize your automated protocols in clinical laboratories
5. What patients want: A story of choice, clinical trials & evidence-based medicine
6. ZyStor seeks to raise $15M for clinical trials
7. Prodesse begins clinical trials for flu virus detection
8. ConjuGon raises $3.3 million to fund clinical trials
9. Cancer-fighting agent heads for clinical trials
10. Quintessence cancer treatment chosen for clinical studies
11. Third Wave reports clinical growth, continued loss

Post Your Comments:

Arpida Presents Preclinical and Clinical Data on Iclapri...(structure infections. An NDA filing is e...)